CiPA (Comprehensive In Vitro Pro-Arrhythmia Assay) is a scientific CSRC/HESI/FDA/SPS-sponsored proposal that aims to define a novel integrated preclinical in vitro/in silico paradigm in which the proarrhythmic potential of new drugs would be primarily assessed using nonclinical in vitro human models
On October 1, 2014, the Scientific Liaison Coalition (SLC) will host a webinar, Progress Made on Tox21: A Framework for the Next Generation of Risk Science, presented by Daniel Krewski.
On behalf of the Society, I am pleased to announce that registration is now open for the CSRC/HESI/FDA/SPS CIPA Update Workshop on December 11, 2014. This is a follow-up meeting to the July 2013 workshop on Rechanneling the Current Cardiac Paradigm.
The workshop will be held at the